96
Participants
Start Date
April 23, 2019
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
AMDC-USR (iltamiocel)
Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
Placebo
Placebo control is the vehicle solution used for the study product.
Columbia University Irving Medical Center, New York
Northwell Health/The Arthur Smith Institute for Urology, Lake Success
AccuMed Research Associates, Garden City
Magee Women's Hospital of UPMC, Pittsburgh
MedStar Georgetown Hospital Department of Urology, Washington D.C.
Atrium Health, Charlotte
Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville
Cleveland Clinic/Glickman Institute-Q10, Cleveland
Bennett Institute of Urogynecology and Incontinence, Grand Rapids
Sanford Female Pelvic Medicine and Reconstructive Surgery Clinic, Sioux Falls
University of Kansas Health System, Kansas City
Cedar Health Research, Irving
Houston Methodist Hospital, Houston
Arizona Urology Specialists, Tucson
University of New Mexico Women's Care Clinic, Albuquerque
UCLA Women's Health Clinical Research Unit/Department of OBGYN, Los Angeles
American Association of Female Pelvic Medicines Research Institute, Westlake Village
San Diego Clinical Trials, La Mesa
Stanford Hospital and Clinics, Stanford
Virginia Mason Medical Center, Seattle
Derriford Hospital, Plymouth
Lead Sponsor
Cook MyoSite
INDUSTRY